{
    "pubmed_id": 35085183,
    "study_identifier": "PMID35085183_study-01",
    "study_name": "Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients",
    "publication_title": "Higher Proinflammatory Cytokines Are Associated With Increased Antibody Titer After a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients",
    "study_objective": "To determine if prevaccination cytokine levels are associated with antibody response to SARS-CoV-2 vaccination",
    "study_description": "Background: Solid organ transplant recipients (SOTRs) are at increased risk for severe COVID-19 and exhibit lower antibody responses to SARS-CoV-2 vaccines. This study aimed to determine if prevaccination cytokine levels are associated with antibody response to SARS-CoV-2 vaccination. Methods: A cross-sectional study was performed among 58 SOTRs before and after two-dose mRNA vaccine series, 35 additional SOTRs before and after a third vaccine dose, and comparison to 16 healthy controls (HCs). Antispike antibody was assessed using the IgG Euroimmun ELISA. Electrochemiluminescence detection-based multiplexed sandwich immunoassays (Meso Scale Diagnostics) were used to quantify plasma cytokine and chemokine concentrations (n = 20 analytes) and compare concentrations between SOTRs and HCs, stratified by ultimate antibody response to the vaccine using Wilcoxon-rank-sum test with false discovery rates computed to correct for multiple comparisons. Results: In the study population, 100% of HCs, 59% of SOTRs after 2 doses and 63% of SOTRs after 3 doses had a detectable antibody response. Multiple baseline cytokines were elevated in SOTRs versus HCs. There was no significant difference in baseline cytokine levels between SOTRs with high versus low-titer antibodies after 2 doses of vaccine. However, as compared with poor antibody responders, SOTRs who went on to develop a high-titer antibody response to a third dose of vaccine had significantly higher prethird dose levels of several innate immune cytokines including IL-17, IL-2Ra, IL-6, IP-10, MIP-1\u03b1, and TNF-\u03b1 (false discovery rates < 0.05). Conclusions: A specific inflammatory profile may be associated with developing higher antibodies in response to a third dose of SARS-CoV-2 vaccine in SOTRs.",
    "primary_institution_name": "Johns Hopkins University",
    "study_personnel": [
        {
            "personnel_id": "PMID35085183_personnel-01",
            "honorific": "",
            "last_name": "Klein",
            "first_name": "Sabra",
            "suffixes": "",
            "organization": "Johns Hopkins University",
            "orchid_id": "",
            "email": "sklein2@jhu.edu",
            "seronet_title_in_study": "SeroNet Principal Investigator",
            "role_in_study": "Investigator",
            "site_name": "Johns Hopkins University"
        },
        {
            "personnel_id": "PMID35085183_personnel-02",
            "honorific": "",
            "last_name": "Cox",
            "first_name": "Andrea",
            "suffixes": "",
            "organization": "Johns Hopkins University",
            "orchid_id": "",
            "email": "acox@jhmi.edu",
            "seronet_title_in_study": "SeroNet Co-Principal Investigator",
            "role_in_study": "Investigator",
            "site_name": "Johns Hopkins University"
        },
        {
            "personnel_id": "PMID35085183_personnel-03",
            "honorific": "",
            "last_name": "Bailey",
            "first_name": "Justin",
            "suffixes": "",
            "organization": "Johns Hopkins University",
            "orchid_id": "",
            "email": "jbailey7@jhu.edu",
            "seronet_title_in_study": "SeroNet Investigator",
            "role_in_study": "Investigator",
            "site_name": "Johns Hopkins University"
        },
        {
            "personnel_id": "PMID35085183_personnel-04",
            "honorific": "",
            "last_name": "Karaba",
            "first_name": "Andrew",
            "suffixes": "",
            "organization": "Johns Hopkins University",
            "orchid_id": "",
            "email": "andrew.karaba@jhmi.edu",
            "seronet_title_in_study": "SeroNet Investigator",
            "role_in_study": "Corresponding Author",
            "site_name": "Johns Hopkins University"
        }
    ],
    "study_file": [
        {
            "study_file_name": "PMID35085183_sdc1.pdf",
            "study_file_description": "Supplementary data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID35085183 data.xlsx",
            "study_file_description": "Demographic data and Cytokine data",
            "study_file_type": "Demographics"
        },
        {
            "study_file_name": "PMID35085183_v1.2.4",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Immune Response",
    "study_type": "Serosurveillance",
    "keyword": [
        "Antibodies",
        "Viral",
        "COVID-19 Vaccines-adverse effects",
        "COVID-19-prevention & control",
        "Cross-Sectional Studies",
        "Cytokines",
        "Humans",
        "Organ Transplantation-adverse effects",
        "SARS-CoV-2",
        "Transplant Recipients",
        "Vaccines",
        "Synthetic",
        "mRNA Vaccines"
    ],
    "clinical_study_design": "Cross-sectional Study",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID35085183_protocol-01",
        "protocol_file_name": "PMID35085183_protocol-01.txt",
        "protocol_name": "PMID35085183_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19",
        "Solid Organ Transplant Recipient"
    ],
    "sars_cov_2_vaccine_type": [
        "Johnson & Johnson",
        "Moderna",
        "Pfizer-BioNTech"
    ],
    "clinical_outcome_measure": "Antispike antibody, plasma cytokine and  chemokine concentrations",
    "enrollment_start_date": "",
    "enrollment_end_date": "",
    "number_of_study_subjects": 109,
    "age_unit": "Years",
    "minimum_age": 20,
    "maximum_age": 79,
    "study_human_cohort": [
        {
            "arm_id": "PMID35085183_human_subject-01",
            "arm_name": "SOTRs with 2-dose of mRNA vaccine",
            "study_population_description": "58 SOTRs before and after two-dose mRNA vaccine series",
            "arm_type": "Observational",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Other"
            ],
            "race_specify": [
                "White",
                "Asian",
                "Black or African American",
                "Multiracial"
            ],
            "description": "",
            "sex_at_birth": [
                "Male",
                "Female"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Maryland"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Moderna COVID-19 vaccine ; VO:0005157",
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35085183_human_subject-02",
            "arm_name": "SOTRs with 3-dose of mRNA vaccine",
            "study_population_description": "35 SOTRs with a third vaccine dose",
            "arm_type": "Observational",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Other"
            ],
            "race_specify": [
                "White",
                "Other",
                "Multiracial"
            ],
            "description": "",
            "sex_at_birth": [
                "Male",
                "Female"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Maryland"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated"
            ],
            "sars_cov_2_vaccine_type": [
                "Johnson & Johnson COVID-19 vaccine; VO:0005159",
                "Moderna COVID-19 vaccine ; VO:0005157",
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        },
        {
            "arm_id": "PMID35085183_human_subject-03",
            "arm_name": "Healthy controls",
            "study_population_description": "16 healthy controls (HCs)",
            "arm_type": "Healthy Control",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Other"
            ],
            "race_specify": [
                "White",
                "Asian",
                "Black or African American"
            ],
            "description": "",
            "sex_at_birth": [
                "Male",
                "Female"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: Maryland"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID35085183_visit-01",
            "visit_name": "Blood samples collected from 0 to 4 weeks in the participants from 2-dose cohort before vaccination",
            "visit_order_number": 1,
            "visit_min_start_day": 0,
            "visit_max_start_day": 28,
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35085183_visit-02",
            "visit_name": "Blood samples collected 2 weeks after vaccine doses from the 2-dose cohort participants",
            "visit_order_number": 2,
            "visit_min_start_day": 14,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35085183_visit-03",
            "visit_name": "Blood sample collected 0 to 22 days (median 1 [IQR 0\u20135] d) before dose 3 (median of 83 d after dose 2) from the 3-dose cohort participants",
            "visit_order_number": 3,
            "visit_min_start_day": 83,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        },
        {
            "visit_id": "PMID35085183_visit-04",
            "visit_name": "Blood sample collected 2 weeks after dose 3 from the 3-dose cohort participants",
            "visit_order_number": 4,
            "visit_min_start_day": 194,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID35085183_human_subject-01, PMID35085183_human_subject-02, PMID35085183_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID35085183_visit-01"
            ],
            "assay_type": "ELISA",
            "experiment_name": "SARS-CoV-2 Antibody Detection",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Pre-vaccination"
            ],
            "sars_cov_2_antigen": [
                "S1"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "Euroimmun",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35085183_human_subject-01, PMID35085183_human_subject-02, PMID35085183_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID35085183_visit-02 | PMID35085183_visit-03 | PMID35085183_visit-04"
            ],
            "assay_type": "ELISA",
            "experiment_name": "SARS-CoV-2 Antibody Detection",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "S1"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "Euroimmun",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35085183_human_subject-01, PMID35085183_human_subject-02, PMID35085183_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID35085183_visit-01"
            ],
            "assay_type": "ELISA",
            "experiment_name": "Pseudoneutralization/ACE2 Inhibition Measurement",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Pre-vaccination"
            ],
            "sars_cov_2_antigen": [
                "S1"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "Euroimmun",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35085183_human_subject-01, PMID35085183_human_subject-02, PMID35085183_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID35085183_visit-02 | PMID35085183_visit-03 | PMID35085183_visit-04"
            ],
            "assay_type": "ELISA",
            "experiment_name": "Pseudoneutralization/ACE2 Inhibition Measurement",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "S1"
            ],
            "assay_use": "FDA EUA",
            "manufacture": "Euroimmun",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Arbitrary Unit",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35085183_human_subject-01, PMID35085183_human_subject-02, PMID35085183_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID35085183_visit-01"
            ],
            "assay_type": "Multiplex Bead Array Assay",
            "experiment_name": "Cytokines and chemokines measurement",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Pre-vaccination"
            ],
            "sars_cov_2_antigen": [],
            "assay_use": "",
            "manufacture": "Meso Scale Diagnostics",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID35085183_human_subject-01, PMID35085183_human_subject-02, PMID35085183_human_subject-03"
            ],
            "associated_first_planned_visit_id": [
                "PMID35085183_visit-02 | PMID35085183_visit-03 | PMID35085183_visit-04"
            ],
            "assay_type": "Multiplex Bead Array Assay",
            "experiment_name": "Cytokines and chemokines measurement",
            "experiment_results_file_name": "na",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [],
            "assay_use": "",
            "manufacture": "Meso Scale Diagnostics",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "Other"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        }
    ],
    "geriatric_subjects": "Yes",
    "pediatric_subjects": "No",
    "pregnant_subjects": "No",
    "sars_cov_2_antibodies_measured": "Yes",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID35085183_inexcl-01",
            "inclusion_criterion": "Geriatric subjects",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35085183_inexcl-02",
            "inclusion_criterion": "Pediatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35085183_inexcl-03",
            "inclusion_criterion": "Pregnant subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35085183_inexcl-04",
            "inclusion_criterion": "SARS-CoV-2 Antibodies Measured",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID35085183_inexcl-05",
            "inclusion_criterion": "Vaccinated  Solid Organ Transplant Recipients",
            "inclusion_criterion_category": "inclusion"
        }
    ]
}
